Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,849 active trials61 approved drugs306 evidence items
- NCIt
- C156482
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,388 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06216496 | Evaluation of Amino Acid Metabolism Changes in Ovarian Cancer(AMINOCANCER) | recruiting | N/A | 23 | University Hospital, GrenobleOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT06420973 | RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression | recruiting | Phase 2 | 54 | Peking University Cancer Hospital & InstituteOTHER | 1 | May 20, 2024 | clinicaltrials |
| NCT06417736 | Prospective Study for Endometrial Carcinoma and Hyperplasia in Childbearing-age Women | recruiting | N/A | 75 | Women's Hospital School Of Medicine Zhejiang UniversityOTHER | 1 | May 16, 2024 | clinicaltrials |
| NCT06413992 | Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer | recruiting | Phase 2 | 117 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT05397262 | Organ-preservative Therapy of Bladder Cancer With Radiotherapy or Radiochemotherapy Combined With Hyperthermia(HyBla_RCT) | recruiting | N/A | 1,000 | University of Erlangen-Nürnberg Medical SchoolOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT05763511 | Improved Diagnosis of Ovarian Cancer by Use of Circulating Tumor DNA as a Biomarker | recruiting | — | 300 | University of AarhusOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT05842629 | Improved Diagnosis of Ovarian Cancer | recruiting | — | 1,700 | University of AarhusOTHER | 1 | May 9, 2024 | clinicaltrials |
| NCT06404671 | Timing of Surgery After Neoadjuvant Chemotherapy for Advanced Ovarian Cancer | recruiting | N/A | 250 | Alexandria UniversityOTHER | 1 | May 8, 2024 | clinicaltrials |
| NCT06251947 | Efbemalenograstim Alfa Injection for Ovarian or Cervical Cancer Receiving Chemotherapy Regimen | recruiting | Phase 2 | 83 | Shandong UniversityOTHER | 1 | May 7, 2024 | clinicaltrials |
| NCT05539677 | Biobank and Register of Patients With Agresive Tumors for Translational and Analytical Research(REGATA) | recruiting | — | 1,000 | N.N. Petrov National Medical Research Center of OncologyOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT06397755 | Observational Study of Patients Who Underwent Diagnostic Investigation (Prostate Biopsy) and/or Radical Prostatectomy Surgery. | recruiting | — | 20,000 | IRCCS San RaffaeleOTHER | 1 | May 3, 2024 | clinicaltrials |
| NCT05797831 | Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer | recruiting | Phase 2 / Phase 3 | 268 | Kartos Therapeutics, Inc.INDUSTRY | 17 | May 2, 2024 | clinicaltrials |
| NCT06395844 | Safety and Efficacy of Intraperitoneal Injection of METR-NK Cells as Neoadjuvant Therapy for Advanced Epithelial Ovarian Cancer | recruiting | Phase 1 / Phase 2 | 28 | Anhui Provincial Cancer HospitalOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT05868174 | Combination of 177Lu-TLX250 and Peposertib in Patients With Carbonic Anhydrase IX -Expressing Solid Tumors | recruiting | Phase 1 | 36 | Telix Pharmaceuticals (Innovations) Pty LimitedINDUSTRY | 1 | May 1, 2024 | clinicaltrials |
| NCT06357416 | The Man Van Project(MV) | recruiting | N/A | 4,000 | Royal Marsden NHS Foundation TrustOTHER | 1 | May 1, 2024 | clinicaltrials |
| NCT06391190 | Concurrent Chemoradiotherapy Followed by PD-1 Inhibitor in Advanced Cervical Cancer | recruiting | Phase 1 / Phase 2 | 20 | RenJi HospitalOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT06389409 | Study on the Quality of Life and Functional/Oncological Outcome of Testicular Cancer Patients | recruiting | — | 3,000 | IRCCS San RaffaeleOTHER | 1 | Apr 29, 2024 | clinicaltrials |
| NCT03749980 | MyVHL: Patient Natural History Study(MyVHL) | recruiting | — | 10,000 | Joshua Mann, MPHOTHER | 1 | Apr 26, 2024 | clinicaltrials |
| NCT06387056 | Genomic Biomarker-guided Neoadjuvant Therapy for Prostate Cancer (SEGNO)(SEGNO) | recruiting | Phase 2 | 40 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Apr 26, 2024 | clinicaltrials |
| NCT06256224 | Toripalimab Combined With Definitive CCRT for LACC Patients | recruiting | N/A | 150 | Ruijin HospitalOTHER | 1 | Apr 24, 2024 | clinicaltrials |
| NCT05817214 | Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer | recruiting | Phase 2 | 35 | Zhongnan HospitalOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT04641936 | Urine Omics Predicting IO Therapy Responses in mUC Patients | recruiting | — | 600 | National Taiwan University HospitalOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05027776 | Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years | recruiting | Phase 3 | 1,348 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05371353 | Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine | recruiting | — | 600 | Shanghai Bovax Biotechnology Co., Ltd.INDUSTRY | 1 | Apr 17, 2024 | clinicaltrials |
| NCT06354738 | Improving Endometrial Cancer Assessment by Combining Genomic Profiling and Surgical Assessment(EUGENIE) | recruiting | N/A | 1,000 | University Hospital, GasthuisbergOTHER | 1 | Apr 17, 2024 | clinicaltrials |
| NCT05905315 | Primary Chemoradiation VS. Neoadjuvant Chemotherapy Followed By Surgery As Treatment Strategy For LAVC(VULCANIZE-II) | recruiting | Phase 2 | 98 | The Netherlands Cancer InstituteOTHER | 1 | Apr 15, 2024 | clinicaltrials |
| NCT04838899 | Stereotactic Ablative Radiation Therapy for Abiraterone-Resistant, Oligoprogressive Metastatic Prostate Cancer | recruiting | N/A | 30 | Sunnybrook Health Sciences CentreOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT05080556 | Adaptive ChemoTherapy for Ovarian Cancer in Patients With Replased Platinum-sensitive High Grade Serous or High Grade Endometrioid Ovarian Cancer(ACTOv) | recruiting | Phase 2 | 80 | University College, LondonOTHER | 1 | Apr 12, 2024 | clinicaltrials |
| NCT06354231 | DV Combined With Toripalimab for Renal Preservation in Solitary Kidney or Renal Insufficiency or Bilateral Multiple UTUC | recruiting | Phase 2 | 20 | Fudan UniversityOTHER | 1 | Apr 11, 2024 | clinicaltrials |
| NCT06336187 | European Active Surveillance of Renal Cell Carcinoma Study (EASE RCC Study)(EASE) | recruiting | — | 400 | Azienda Ospedaliero Universitaria Maggiore della CaritaOTHER | 1 | Apr 10, 2024 | clinicaltrials |
| NCT06350825 | Cytoreductive Prostatectomy Combined With Triple or Dual Systemic Therapy in mHSPC Patients | recruiting | Phase 3 | 200 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Apr 5, 2024 | clinicaltrials |
| NCT05186493 | Laparoscopic Robot-assisted Pelvic Exenteration for Pelvic Primary and Recurrent Cancers | recruiting | N/A | 40 | Oslo University HospitalOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT05447273 | The Role of Functional Magnetic Resonance Imaging in Preoperative Assessment of Primary Penile Carcinoma | recruiting | — | 60 | Oslo University HospitalOTHER | 1 | Apr 3, 2024 | clinicaltrials |
| NCT06341478 | Investigator Grant (IG) 2022 27746 | recruiting | N/A | 153 | IRCCS San RaffaeleOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT06341907 | Application of MRD Combined With Personalized Vaccine in the Treatment of Postoperative Recurrence Prevention of EOC | recruiting | Phase 2 / Phase 3 | 10 | Second Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Apr 2, 2024 | clinicaltrials |
| NCT03973671 | Prospective Sample Collection for Cancer of Bladder(ProCaB) | recruiting | — | 300 | Universitaire Ziekenhuizen KU LeuvenOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT06335693 | Adjuvant Hypofractionated Radiotherapy for Prostate Cancer | recruiting | N/A | 9 | Changhai HospitalOTHER | 1 | Mar 28, 2024 | clinicaltrials |
| NCT06330909 | Image-guided Focal Dose Escalation- Primary pc Treated With Primary External Beam Hypofract.Stereotactic rt(HypoF-SBRT) | recruiting | N/A | 374 | University Hospital FreiburgOTHER | 1 | Mar 26, 2024 | clinicaltrials |
| NCT06265025 | GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors | recruiting | Phase 1 / Phase 2 | 125 | GeneMedicine Co., Ltd.INDUSTRY | 1 | Mar 21, 2024 | clinicaltrials |
| NCT06320223 | PROMISE PET Registry on PSMA-PET and Outcome in Prostate Cancer(PROMISE-PET) | recruiting | — | 10,000 | University Hospital, EssenOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT06321679 | Response Evaluation of Cancer Therapeutics in Metastatic Castration-Resistant Prostate Cancer to the Bone(RESPECT) | recruiting | — | 40 | European Institute of OncologyOTHER | 1 | Mar 20, 2024 | clinicaltrials |
| NCT06318559 | Artificial Intelligence 3D Augmented Reality Robot-Assisted-Radical- Prostatectomy v.s. no3D Intervention(RIDERS) | recruiting | N/A | 120 | Fondazione del Piemonte per l'OncologiaOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT05116475 | Evaluation of dAroLutamide Addition to anDrogen Deprivation Therapy and radIatioN Therapy in Newly Diagnosed Prostate Cancer With Pelvic Lymph Nodes Metastases(ALADDIN) | recruiting | Phase 3 | 152 | Association Pour La Recherche des Thérapeutiques Innovantes en CancérologieOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06305832 | Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer | recruiting | Phase 2 | 102 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06307249 | Precision Therapy for Solid Tumors: Synergistic CDK4/6 Inhibition and Anti-VEGF Targeting LncRNA(PTST_PALBEVA) | recruiting | Phase 1 | 50 | Lebanese UniversityOTHER | 1 | Mar 12, 2024 | clinicaltrials |
| NCT06292897 | Using Tissue-based Spatial Data to Understand How Obesity-related Tumor Metabolites Fuel Prostate Cancer Progression(OBESITA'&PCa) | recruiting | — | 25 | Fondazione IRCCS Ca' Granda, Ospedale Maggiore PoliclinicoOTHER | 1 | Mar 5, 2024 | clinicaltrials |
| NCT04612907 | Different Fractionation Schedules of Radiotherapy to the Primary Tumour in Metastatic Hormone Sensitive Prostate Cancer(Hypo-M1) | recruiting | N/A | 420 | Umeå UniversityOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT04642027 | PSMA-PET Guided Hypofractionated Salvage Prostate Bed Radiotherapy(PERYTON) | recruiting | Phase 3 | 538 | University Medical Center GroningenOTHER | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06155396 | A Study of RC48-ADC Combination With Zimberelimab Injection Therapies at Least First-line Platinum-containing Standard Therapy Failed With Recurrent or Metastatic Cervical Cancer | recruiting | Phase 2 | 116 | RemeGen Co., Ltd.INDUSTRY | 1 | Feb 28, 2024 | clinicaltrials |
| NCT06206083 | Molecular Classification in Mexican Patients With Endometrial Cancer and Its Impact on Prognosis | recruiting | — | 64 | National Institute of CancerologíaOTHER_GOV | 1 | Feb 28, 2024 | clinicaltrials |
Data updated 23 days agoSource updated May 20, 2024source: clinicaltrials